Risdiplam Delivers An Improvement to Infants with Spinal Muscular Atrophy Type 1
source: pixabay.com

Risdiplam Delivers An Improvement to Infants with Spinal Muscular Atrophy Type 1

Genentech (Roche Group) announced positive results of its FIREFISH trial in a recent Business Wire news release.  The second part of the study evaluated risdiplam’s efficacy on infants ages one…

Continue Reading Risdiplam Delivers An Improvement to Infants with Spinal Muscular Atrophy Type 1

Clinical Trials Show Promising Results for Risdiplam in Treatment of Spinal Muscular Atrophy Types 1, 2, and 3

According to a recent article in SMA News Today, risdiplam (formerly RG7916)  is in ongoing studies of patients with spinal muscular atrophy (SMA). The drug is an investigational medicine developed by Genentech…

Continue Reading Clinical Trials Show Promising Results for Risdiplam in Treatment of Spinal Muscular Atrophy Types 1, 2, and 3

New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy

  According to an article in Biospace, the FDA is currently reviewing data from the Phase III STRIVE clinical trial for possible approval of Zolgensma as gene therapy for spinal…

Continue Reading New Drug Under Review by the FDA to Treat the Most Lethal Form of Spinal Muscular Atrophy